Adaptive Biotechnologies — Third Quarter 2026 Earnings Summary

Adaptive Biotechnologies reported total company profitability in the third quarter of 2026 with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million. The company generated $83.9 million in revenue for the quarter, driven by a 28% increase in Minimal Residual Disease (MRD) revenue to $72.6 million, while Immune Medicine revenue declined to $11.3 million. Adaptive Biotechnologies raised its full-year 2026 MRD revenue guidance to a range of $276 million to $286 million, reflecting 30% to 35% annual growth. Recent regulatory developments, including new NCCN Guidelines and an International Myeloma Working Group definition of cure, are expected to further support the demand for MRD testing.